Primary Purpose
| primary_purpose | Study_Count |
|---|---|
| Treatment | 998 |
| Supportive Care | 21 |
| Diagnostic | 13 |
| Prevention | 12 |
| Other | 7 |
| Basic Science | 5 |
| Screening | 2 |
| NA | 2 |
| Educational/Counseling/Training | 1 |
Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
| Type | Study_count |
|---|---|
| Total_Studies | 1141 |
| interventional | 1061 |
| Observational | 70 |
| Registry | 10 |
```
| intervention_type | Study_Count |
|---|---|
| Drug | 531 |
| Biological | 105 |
| Biological|Drug | 67 |
| Drug|Other | 67 |
| Biological|Drug|Other | 32 |
| Drug|Procedure | 30 |
| Biological|Drug|Procedure|Radiation | 25 |
| Biological|Other | 18 |
| Drug|Procedure|Radiation | 16 |
| Drug|Other|Procedure|Radiation | 12 |
| Drug|placebo | 11 |
| Drug|Radiation | 11 |
| Procedure | 11 |
| Biological|Drug|Other|Procedure|Radiation | 10 |
| Biological|Drug|Other|Procedure | 8 |
| Biological|Drug|Procedure | 8 |
| Other | 8 |
| Biological|Drug|Radiation | 7 |
| Drug|Other|Procedure | 7 |
| Biological|Other|Procedure | 6 |
| Drug|Genetic | 6 |
| Biological|Radiation | 5 |
| Device | 5 |
| Drug|Genetic|Other | 4 |
| Radiation | 4 |
| Behavioral | 3 |
| Device|Drug|Procedure | 3 |
| Dietary Supplement|Other | 3 |
| Biological|Device|Drug | 2 |
| Biological|Drug|Genetic | 2 |
| Biological|Procedure | 2 |
| Biological|Procedure|Radiation | 2 |
| Combination Product|Drug | 2 |
| Diagnostic Test | 2 |
| Genetic | 2 |
| Other|Procedure | 2 |
| Behavioral|Drug | 1 |
| Biological|Device|Drug|Procedure|Radiation | 1 |
| Biological|Dietary Supplement|placebo | 1 |
| Biological|Drug|Genetic|Other | 1 |
| Biological|Drug|Genetic|Other|Procedure | 1 |
| Biological|Drug|Other|Radiation | 1 |
| Biological|Genetic|Other | 1 |
| Combination Product | 1 |
| Device|Drug | 1 |
| Device|Procedure | 1 |
| Diagnostic Test|Drug|Genetic|Procedure|Radiation | 1 |
| Diagnostic Test|Drug|Procedure | 1 |
| Dietary Supplement | 1 |
| Dietary Supplement|Drug | 1 |
| Dietary Supplement|Other|placebo | 1 |
| Drug|Genetic|Other|Procedure|Radiation | 1 |
| Drug|Genetic|Procedure | 1 |
| Drug|Genetic|Procedure|Radiation | 1 |
| Drug|Other|placebo|Procedure | 1 |
| Drug|Other|Radiation | 1 |
| Drug|placebo|Procedure | 1 |
| Genetic|Radiation | 1 |
| Country | Study_Count |
|---|---|
| United States | 588 |
| NA | 44 |
| China | 43 |
| United States|Canada | 34 |
| Germany | 25 |
| Canada | 21 |
| Japan | 18 |
| France | 17 |
| United States|Puerto Rico | 14 |
| Italy | 13 |
| Korea, Republic of | 10 |
| Spain | 9 |
| United Kingdom | 8 |
| Taiwan | 7 |
| United States|Australia|Canada | 5 |
| United States|Germany|Italy | 5 |
| United States|United Kingdom | 5 |
| United States|Australia | 4 |
| United States|France | 4 |
| United States|Italy | 4 |
| Israel | 3 |
| Russian Federation | 3 |
| United States|Canada|France|Netherlands | 3 |
| United States|Germany | 3 |
| Belgium|France | 2 |
| France|United Kingdom | 2 |
| Italy|Switzerland | 2 |
| Japan|Korea, Republic of | 2 |
| Norway | 2 |
| Switzerland | 2 |
| United States|Canada|Puerto Rico | 2 |
| United States|Denmark|Germany | 2 |
| United States|France|Germany|Spain | 2 |
| United States|France|Spain|United Kingdom | 2 |
| United States|France|United Kingdom | 2 |
| United States|Korea, Republic of | 2 |
| United States|Switzerland | 2 |
| Albania|Argentina|Australia|Bosnia and Herzegovina|Brazil|Bulgaria|Colombia|Croatia|Ecuador|Egypt|Finland|Germany|Greece|Israel|Italy|Mexico|Romania|Russian Federation|Slovakia|Slovenia|Spain|Sweden|Switzerland|Turkey | 1 |
| Albania|Argentina|Austria|Brazil|Bulgaria|Colombia|Ecuador|Egypt|France|Germany|Greece|Hungary|Italy|Lithuania|Norway|Romania|Russian Federation|Slovakia|Slovenia|Spain|Sweden|Switzerland|Turkey|United Kingdom | 1 |
| Algeria|Morocco|Tunisia | 1 |
| Argentina | 1 |
| Australia|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Canada|Colombia|Croatia|Denmark|Finland|France|Georgia|Germany|Greece|Italy|Macedonia, The Former Yugoslav Republic of|Malaysia|Mexico|New Zealand|Peru|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Thailand|Turkey|United Kingdom | 1 |
| Australia|Belgium|Denmark|Italy|Spain | 1 |
| Australia|Canada|France|Italy|Sweden|Switzerland | 1 |
| Australia|France|Germany|Hungary|Korea, Republic of|Poland|Singapore|United Kingdom | 1 |
| Australia|France|Germany|Italy|Spain|United Kingdom | 1 |
| Australia|France|Spain|United Kingdom | 1 |
| Austria | 1 |
| Austria|Belgium|China|Czechia|Denmark|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Netherlands|Norway|Poland|Portugal|Russian Federation|Slovakia|Spain|Sweden|Switzerland | 1 |
| Austria|Belgium|Finland|France|Germany|Italy|Japan|Netherlands|Spain|Switzerland|United Kingdom | 1 |
| Austria|Belgium|France|Germany|Israel|Netherlands|Poland|Portugal | 1 |
| Belgium | 1 |
| Belgium|Canada|China|France|Hungary|Italy|Netherlands|Poland|Spain|United Kingdom | 1 |
| Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Norway|Portugal|Spain|Sweden|Switzerland|United Kingdom | 1 |
| Belgium|Croatia|Czechia|Hungary|Poland|Portugal|Romania|Spain|Turkey|United Kingdom | 1 |
| Belgium|Croatia|Egypt|France|Netherlands | 1 |
| Belgium|Denmark|Italy|Spain|United Kingdom | 1 |
| Belgium|Egypt|France|Netherlands|Portugal|Switzerland|United Kingdom | 1 |
| Belgium|France|United Kingdom | 1 |
| Belgium|Lithuania|Spain | 1 |
| Belgium|Netherlands | 1 |
| Brazil | 1 |
| Brazil|Bulgaria|China|Greece|Italy|Korea, Republic of|Poland|Portugal|Russian Federation|South Africa|Taiwan|Turkey | 1 |
| Brazil|United States|Argentina|Austria|Belgium|Canada|Croatia|Denmark|Greece|Italy|Netherlands|Poland|Spain|Sweden|Switzerland|Turkey|United Kingdom | 1 |
| Canada|United States | 1 |
| Canada|United States|Australia|New Zealand|Switzerland | 1 |
| Chile|Italy|Spain|Switzerland | 1 |
| Colombia|India|Russian Federation|South Africa|Ukraine | 1 |
| Colombia|Mexico | 1 |
| Denmark|Finland|Netherlands|Norway|Sweden | 1 |
| Finland | 1 |
| France|Germany | 1 |
| France|Germany|Korea, Republic of | 1 |
| France|Italy|Japan|Spain | 1 |
| France|Italy|Netherlands | 1 |
| France|Italy|Peru|Puerto Rico|Spain|Switzerland | 1 |
| France|Italy|Spain|United Kingdom | 1 |
| France|Italy|Switzerland | 1 |
| France|Spain | 1 |
| Germany|Italy|Spain | 1 |
| Germany|Netherlands|United Kingdom | 1 |
| Germany|Switzerland | 1 |
| Germany|United States|Belgium|France|Spain|Switzerland|United Kingdom | 1 |
| Hungary|Argentina|Australia|Austria|Brazil|Canada|Chile|Colombia|Croatia|Denmark|Dominican Republic|Egypt|El Salvador|Germany|Guatemala|Hong Kong|Indonesia|Italy|Korea, Republic of|Malaysia|Netherlands|New Zealand|Panama|Peru|Philippines|Portugal|Romania|Sweden|Taiwan|Thailand|Turkey|Vietnam | 1 |
| India | 1 |
| Italy|Japan|United States|Australia|France|Greece | 1 |
| Italy|Saudi Arabia|United Kingdom | 1 |
| Italy|United Kingdom | 1 |
| Japan|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Chile|China|Colombia|France|Germany|Greece|Hong Kong|Hungary|Ireland|Italy|Korea, Republic of|Lithuania|Malaysia|Mexico|New Zealand|Philippines|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|Vietnam | 1 |
| Japan|United States|Argentina|Australia|Belgium|Brazil|China|France|Germany|Israel|Korea, Republic of|Poland|Puerto Rico|Russian Federation|Spain|Sweden|Turkey|Ukraine|United Kingdom | 1 |
| Kenya|Zimbabwe | 1 |
| Mexico | 1 |
| Netherlands | 1 |
| Netherlands|Australia|Belgium|Canada|Denmark|Egypt|France|Hungary|Italy|New Zealand|Norway|Poland|Portugal|Slovakia|Slovenia|South Africa|Sweden|United Kingdom | 1 |
| Puerto Rico | 1 |
| Saudi Arabia | 1 |
| Serbia | 1 |
| Singapore | 1 |
| Spain|France|Germany|Italy|Netherlands|Sweden|United Kingdom | 1 |
| Spain|United States|Australia|Bulgaria|Canada|Colombia|Czechia|France|Georgia|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Romania|Ukraine | 1 |
| Spain|United States|Belgium|Germany|Hungary|Italy|Poland | 1 |
| Sweden|United Kingdom | 1 |
| Switzerland|Austria|Germany|Greece|Italy | 1 |
| Turkey | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|China|Cyprus|Czech Republic|Finland|France|Germany|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|New Zealand|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Slovakia|South Africa|Spain|Sweden|Thailand|Ukraine|United Kingdom | 1 |
| United States|Argentina|Bulgaria|Costa Rica|Ecuador|Estonia|France|Germany|Hungary|India|Italy|Mexico|Panama|Peru|Poland|Romania|Russian Federation|Ukraine|United Kingdom|Uruguay | 1 |
| United States|Australia|Austria|Belgium|Bulgaria|Canada|Finland|France|Germany|Greece|Hong Kong|Hungary|Ireland|Israel|Italy|Korea, Republic of|New Zealand|Poland|Portugal|Russian Federation|Singapore|Spain|Sweden|Turkey|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Canada|Croatia|Czechia|Denmark|Finland|France|Hungary|Ireland|Israel|Italy|Korea, Republic of|Netherlands|Norway|Poland|Singapore|Spain|Sweden|Switzerland|Turkey|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|China|France|New Zealand|Poland|Spain|Taiwan | 1 |
| United States|Australia|Austria|Belgium|Czechia|France|Germany|Italy|Japan|Netherlands|Singapore|Spain|Switzerland|Taiwan | 1 |
| United States|Australia|Austria|Canada|Czechia|France|Hungary|Italy|Netherlands|Spain | 1 |
| United States|Australia|Austria|Canada|Denmark|Finland|France|Italy|Japan|Netherlands|Norway|Spain | 1 |
| United States|Australia|Austria|France|Germany|Hong Kong|Italy|Japan|Netherlands|Norway|Singapore|Spain|Switzerland | 1 |
| United States|Australia|Belarus|Bulgaria|Canada|China|Czechia|France|Germany|Italy|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|China|Czechia|Denmark|Finland|France|Germany|Greece|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|China|Czechia|Finland|France|Germany|Hungary|Israel|Italy|Japan|Russian Federation|Spain|Sweden|Taiwan|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Czechia|Denmark|Finland|France|Italy|New Zealand|Poland|Spain|Taiwan | 1 |
| United States|Australia|Belgium|Canada|Czechia|France|Greece|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Turkey | 1 |
| United States|Australia|Belgium|Canada|France|Germany|Italy|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Italy|Puerto Rico|Spain|United Kingdom | 1 |
| United States|Australia|Belgium|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Poland|Spain|Switzerland|United Kingdom | 1 |
| United States|Australia|Brazil|Canada|Mexico|New Zealand|Peru | 1 |
| United States|Australia|Brazil|India|Mexico|Peru | 1 |
| United States|Australia|Canada|Denmark|France|Germany|Italy|Spain|United Kingdom | 1 |
| United States|Australia|Canada|France|Germany|Korea, Republic of|Spain|United Kingdom | 1 |
| United States|Australia|Canada|France|Italy|Korea, Republic of|Poland|Singapore|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Canada|Germany|Israel|Italy | 1 |
| United States|Australia|Canada|Ireland|New Zealand|Puerto Rico|Switzerland | 1 |
| United States|Australia|Canada|Netherlands|New Zealand|Puerto Rico|Switzerland | 1 |
| United States|Australia|Canada|Netherlands|Puerto Rico|Switzerland | 1 |
| United States|Australia|Canada|New Zealand | 1 |
| United States|Australia|Canada|Puerto Rico | 1 |
| United States|Australia|Canada|Puerto Rico|Switzerland | 1 |
| United States|Australia|Czechia|France|Germany|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Serbia | 1 |
| United States|Australia|France|Germany|Israel|Korea, Republic of|Spain | 1 |
| United States|Australia|France|Germany|Italy | 1 |
| United States|Australia|France|Greece|Hong Kong|Poland|Russian Federation|Singapore | 1 |
| United States|Australia|France|Italy|Japan | 1 |
| United States|Australia|France|Poland | 1 |
| United States|Australia|Germany | 1 |
| United States|Australia|Israel|Italy|Korea, Republic of|Poland|Slovakia|Spain|United Kingdom | 1 |
| United States|Austria|Belgium|Bulgaria|Czechia|Denmark|France|Germany|Hungary|Italy|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine|United Kingdom | 1 |
| United States|Austria|Belgium|Canada|Czechia|France|Germany|Italy|Netherlands|Russian Federation|Spain|Sweden|Switzerland|United Kingdom | 1 |
| United States|Austria|Czech Republic|France|Germany|Lithuania|Romania|Russian Federation|Sweden|Turkey|United Kingdom | 1 |
| United States|Austria|Korea, Republic of|Spain | 1 |
| United States|Belarus|Belgium|Bulgaria|Canada|Czechia|France|Georgia|Hungary|Italy|Spain|United Kingdom | 1 |
| United States|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Belgium|Brazil|China|Czechia|France|Germany|Israel|Italy|Japan|Poland|Portugal|Puerto Rico|Russian Federation|Spain|Turkey|United Kingdom | 1 |
| United States|Belgium|Bulgaria|Czechia|Hungary|Italy|Poland|Switzerland|Ukraine | 1 |
| United States|Belgium|Canada|France|Hong Kong|Japan|Korea, Republic of|Singapore|United Kingdom | 1 |
| United States|Belgium|Canada|France|United Kingdom | 1 |
| United States|Belgium|France|Germany|Italy|Japan|Netherlands|Spain|Sweden|Switzerland|United Kingdom | 1 |
| United States|Belgium|France|Italy|Netherlands|Spain | 1 |
| United States|Belgium|France|Italy|Spain | 1 |
| United States|Belgium|Germany|Hong Kong|Hungary|Japan|Korea, Republic of|Netherlands|Singapore | 1 |
| United States|Belgium|Israel | 1 |
| United States|Canada|China|France|Germany|Hong Kong|Italy|Taiwan | 1 |
| United States|Canada|France|Germany|Israel|Netherlands | 1 |
| United States|Canada|France|Germany|Italy|Netherlands | 1 |
| United States|Canada|France|Germany|Italy|Spain|United Kingdom | 1 |
| United States|Canada|France|Germany|Netherlands|United Kingdom | 1 |
| United States|Canada|France|Italy|Spain | 1 |
| United States|Canada|France|Italy|Spain|United Kingdom | 1 |
| United States|Canada|France|Spain | 1 |
| United States|Canada|Germany | 1 |
| United States|Canada|Korea, Republic of|Taiwan | 1 |
| United States|Czechia|Italy|Korea, Republic of|Poland|Russian Federation | 1 |
| United States|Denmark | 1 |
| United States|Egypt|India | 1 |
| United States|France|Germany | 1 |
| United States|France|Germany|Italy|Mexico|Netherlands|Spain|United Kingdom | 1 |
| United States|France|Germany|Italy|Poland|United Kingdom | 1 |
| United States|Germany|Israel|Netherlands | 1 |
| United States|Germany|Puerto Rico | 1 |
| United States|India|Israel | 1 |
| United States|Italy|United Kingdom | 1 |
| United States|Japan | 1 |
| United States|Kenya|Uganda | 1 |
| United States|Netherlands | 1 |
| United States|Poland | 1 |
| United States|Poland|Spain|Sweden | 1 |
| United States|Russian Federation | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 479 |
| 2 | 80 |
| 3 | 51 |
| 4 | 37 |
| 5 | 41 |
| 6 | 21 |
| 7 | 19 |
| 8 | 17 |
| 9 | 14 |
| 10 | 16 |
| 11 | 30 |
| 12 | 13 |
| 13 | 8 |
| 14 | 13 |
| 15 | 8 |
| 16 | 9 |
| 17 | 11 |
| 18 | 6 |
| 19 | 5 |
| 20 | 9 |
| 21 | 9 |
| 22 | 13 |
| 23 | 8 |
| 24 | 1 |
| 25 | 8 |
| 26 | 3 |
| 27 | 7 |
| 28 | 4 |
| 30 | 2 |
| 31 | 5 |
| 32 | 4 |
| 33 | 1 |
| 34 | 5 |
| 35 | 2 |
| 36 | 2 |
| 38 | 4 |
| 39 | 2 |
| 40 | 2 |
| 41 | 5 |
| 42 | 3 |
| 43 | 2 |
| 45 | 2 |
| 46 | 3 |
| 47 | 1 |
| 48 | 3 |
| 51 | 1 |
| 52 | 1 |
| 53 | 2 |
| 56 | 1 |
| 57 | 1 |
| 60 | 1 |
| 62 | 1 |
| 65 | 1 |
| 67 | 1 |
| 68 | 1 |
| 71 | 2 |
| 73 | 1 |
| 76 | 1 |
| 77 | 1 |
| 79 | 1 |
| 81 | 1 |
| 87 | 1 |
| 91 | 2 |
| 92 | 2 |
| 94 | 2 |
| 95 | 1 |
| 98 | 1 |
| 99 | 1 |
| 101 | 1 |
| 104 | 1 |
| 106 | 1 |
| 108 | 1 |
| 111 | 2 |
| 112 | 1 |
| 113 | 2 |
| 114 | 2 |
| 116 | 1 |
| 117 | 1 |
| 118 | 1 |
| 119 | 1 |
| 121 | 1 |
| 128 | 1 |
| 129 | 1 |
| 131 | 1 |
| 134 | 1 |
| 143 | 1 |
| 150 | 1 |
| 152 | 1 |
| 161 | 2 |
| 165 | 1 |
| 167 | 1 |
| 171 | 1 |
| 176 | 1 |
| 178 | 1 |
| 180 | 1 |
| 183 | 1 |
| 190 | 1 |
| 192 | 1 |
| 200 | 1 |
| 206 | 1 |
| 212 | 1 |
| 215 | 1 |
| 222 | 1 |
| 235 | 1 |
| 244 | 1 |
| 246 | 1 |
| 259 | 1 |
| 261 | 1 |
| 483 | 1 |
| Phase | Study_Count |
|---|---|
| Phase 2 | 435 |
| Phase 1 | 305 |
| Phase 1/Phase 2 | 151 |
| Phase 3 | 85 |
| N/A | 49 |
| Phase 4 | 19 |
| Early Phase 1 | 12 |
| Phase 2/Phase 3 | 5 |
| Number_of_Arms | Count_of_Studies |
|---|---|
| 1 | 614 |
| 2 | 185 |
| 3 | 45 |
| 4 | 34 |
| 5 | 10 |
| 6 | 10 |
| 7 | 5 |
| 8 | 7 |
| 9 | 2 |
| 10 | 2 |
| 12 | 1 |
| 13 | 2 |
| 15 | 1 |
| 17 | 1 |
| NA | 142 |
| Measure | Early.Phase.1 | N.A | Phase.1 | Phase.1.Phase.2 | Phase.2 | Phase.2.Phase.3 | Phase.3 | Phase.4 |
|---|---|---|---|---|---|---|---|---|
| Min. | 6.00000 | 2.0000 | 2.00000 | 1.00000 | 3.00000 | 80.00 | 14.0000 | 12.0000 |
| 1st Qu. | 10.75000 | 19.2500 | 19.00000 | 32.00000 | 31.00000 | 146.75 | 133.5000 | 52.5000 |
| Median | 18.00000 | 41.0000 | 36.00000 | 54.00000 | 48.00000 | 278.50 | 318.0000 | 101.0000 |
| Mean | 45.58333 | 105.2708 | 57.39203 | 74.78523 | 74.13659 | 384.25 | 502.4458 | 191.7368 |
| 3rd Qu. | 30.75000 | 113.5000 | 62.00000 | 92.00000 | 72.00000 | 516.00 | 547.0000 | 294.0000 |
| Max. | 312.00000 | 713.0000 | 746.00000 | 422.00000 | 3279.00000 | 900.00 | 9350.0000 | 650.0000 |
| group_type | Group_Count |
|---|---|
| Experimental | 1375 |
| NA | 142 |
| Active Comparator | 109 |
| Other | 50 |
| Placebo Comparator | 15 |
| No Intervention | 14 |
| Sham Comparator | 1 |
| intervention_model | Study_Count |
|---|---|
| Single Group Assignment | 728 |
| Parallel Assignment | 219 |
| NA | 61 |
| Sequential Assignment | 41 |
| Crossover Assignment | 7 |
| Factorial Assignment | 5 |
| primary_purpose | Study_Count |
|---|---|
| Treatment | 998 |
| Supportive Care | 21 |
| Diagnostic | 13 |
| Prevention | 12 |
| Other | 7 |
| Basic Science | 5 |
| Screening | 2 |
| NA | 2 |
| Educational/Counseling/Training | 1 |
| Country | Study_Count |
|---|---|
| United States | 29 |
| NA | 7 |
| China | 5 |
| Italy | 3 |
| Japan | 3 |
| Korea, Republic of | 3 |
| Canada | 2 |
| France | 2 |
| United Kingdom | 2 |
| Argentina|Brazil|Chile|Colombia|Guatemala|Mexico|Panama | 1 |
| Austria|Belgium|Bulgaria|Czechia|France|Germany|Greece|Poland|Romania | 1 |
| China|Hong Kong|Taiwan | 1 |
| Israel | 1 |
| Macedonia, The Former Yugoslav Republic of | 1 |
| Netherlands | 1 |
| Russian Federation | 1 |
| Serbia | 1 |
| Spain | 1 |
| Sweden | 1 |
| Tanzania|Uganda | 1 |
| United States|Australia|Canada|Puerto Rico | 1 |
| United States|Australia|Canada|Puerto Rico|Switzerland | 1 |
| United States|Canada | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 47 |
| 2 | 1 |
| 3 | 2 |
| 4 | 2 |
| 5 | 1 |
| 6 | 1 |
| 7 | 1 |
| 9 | 1 |
| 12 | 2 |
| 23 | 1 |
| 25 | 1 |
| 28 | 1 |
| 31 | 1 |
| 35 | 1 |
| 42 | 1 |
| 66 | 1 |
| 69 | 1 |
| 75 | 1 |
| 111 | 1 |
| 130 | 1 |
| 183 | 1 |
| Measure | Observational |
|---|---|
| Min | 8.000 |
| 1st Qu | 89.250 |
| Median | 172.000 |
| Mean | 1022.457 |
| 3rd Qu | 773.250 |
| Max | 13433.000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 31 |
| Case-Only | 15 |
| NA | 9 |
| Case-Control | 5 |
| Other | 5 |
| Family-Based | 3 |
| Case Control | 2 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 42 |
| Retrospective | 15 |
| NA | 7 |
| Cross-Sectional | 4 |
| Other | 2 |
| Country | Study_Count |
|---|---|
| China | 3 |
| Korea, Republic of | 2 |
| United States | 2 |
| Belgium|France | 1 |
| Czechia | 1 |
| NA | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 8 |
| 11 | 1 |
| 31 | 1 |
| Measure | Registries |
|---|---|
| Min | 150.00 |
| 1st Qu | 225.00 |
| Median | 400.00 |
| Mean | 3599.50 |
| 3rd Qu | 2996.25 |
| Max | 20000.00 |
| observational_model | Study_Count |
|---|---|
| Cohort | 9 |
| Case-Only | 1 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 8 |
| Other | 2 |
| target_duration | Study_Count |
|---|---|
| 5 Years | 4 |
| 10 Years | 2 |
| 3 Years | 2 |
| 13 Years | 1 |
| 2 Years | 1 |
#If less then 500 trials
#If less then 500 studies
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT04435743 | Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin’s Lymphomas | https://ClinicalTrials.gov/show/NCT04435743 | Recruiting | Ruijin Hospital | 2022-12-31 |
| NCT04434833 | A Single-cell Transcriptome Study in Patients With Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT04434833 | Recruiting | Ruijin Hospital | 2022-06-30 |
| NCT03289182 | An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin’s Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) | https://ClinicalTrials.gov/show/NCT03289182 | Active, not recruiting | Hoffmann-La Roche | 2020-10-26 |
| NCT03260101 | Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | https://ClinicalTrials.gov/show/NCT03260101 | Recruiting | Cellect Biotechnology | 2021-12-31 |
| NCT03065790 | Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide | https://ClinicalTrials.gov/show/NCT03065790 | Active, not recruiting | Abramson Cancer Center of the University of Pennsylvania | 2021-02-06 |
| NCT03042247 | Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma | https://ClinicalTrials.gov/show/NCT03042247 | Recruiting | Federico II University | 2020-06-10 |
| NCT03000192 | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | https://ClinicalTrials.gov/show/NCT03000192 | Active, not recruiting | University Hospital Southampton NHS Foundation Trust | 2020-12-31 |
| NCT02992223 | Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT | https://ClinicalTrials.gov/show/NCT02992223 | Completed | Azienda Ospedaliera Città della Salute e della Scienza di Torino | 2015-07-31 |
| NCT02788084 | Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow | https://ClinicalTrials.gov/show/NCT02788084 | Active, not recruiting | Alberta Health Services, Calgary | 2019-06-30 |
| NCT02682667 | Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols | https://ClinicalTrials.gov/show/NCT02682667 | Recruiting | National Institutes of Health Clinical Center (CC) | 2025-12-01 |
| NCT02633111 | DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas | https://ClinicalTrials.gov/show/NCT02633111 | Recruiting | Memorial Sloan Kettering Cancer Center | 2021-10-31 |
| NCT01676805 | Tissue Collection for Studies of Lymph Cancer | https://ClinicalTrials.gov/show/NCT01676805 | Recruiting | National Institutes of Health Clinical Center (CC) | NA |
| NCT00923442 | Biology Studies of Hematologic Cancers | https://ClinicalTrials.gov/show/NCT00923442 | Enrolling by invitation | National Institutes of Health Clinical Center (CC) | NA |
| NCT00131014 | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies | https://ClinicalTrials.gov/show/NCT00131014 | Recruiting | Dana-Farber Cancer Institute | 2023-01-31 |
| NCT00039676 | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | https://ClinicalTrials.gov/show/NCT00039676 | Recruiting | National Institutes of Health Clinical Center (CC) | NA |
| NCT02559583 | Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin’s Lymphoma (NHL) in Latin America | https://ClinicalTrials.gov/show/NCT02559583 | Completed | Janssen-Cilag Ltd. | 2016-06-30 |
| NCT02486952 | MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma | https://ClinicalTrials.gov/show/NCT02486952 | Completed | Hoffmann-La Roche | 2011-01-31 |
| NCT02434484 | Symbenda Post-Marketing Surveillance (PMS) | https://ClinicalTrials.gov/show/NCT02434484 | Active, not recruiting | Eisai Inc. | 2020-04-30 |
| NCT02199288 | Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin’s Lymphoma: Real-Life Setting | https://ClinicalTrials.gov/show/NCT02199288 | Completed | Hoffmann-La Roche | 2016-07-31 |
| NCT02178475 | Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin’s Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy | https://ClinicalTrials.gov/show/NCT02178475 | Completed | Amgen | 2016-10-28 |
| NCT02139592 | Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) “Relapsed or Refractory CD30+ Hodgkin’s Lymphoma or Anaplastic Large Cell Lymphoma” | https://ClinicalTrials.gov/show/NCT02139592 | Completed | Takeda | 2017-06-30 |
| NCT02072967 | Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT02072967 | Completed | Astellas Pharma Inc | 2015-10-31 |
| NCT01988272 | Imaging Based Dosimetry for Individualized Internal Emitter Therapy | https://ClinicalTrials.gov/show/NCT01988272 | Completed | University of Michigan | 2015-03-31 |
| NCT01763398 | Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study | https://ClinicalTrials.gov/show/NCT01763398 | Completed | Yonsei University | 2015-08-31 |
| NCT01684865 | An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT01684865 | Completed | Hoffmann-La Roche | 2017-11-27 |
| NCT01623856 | Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients | https://ClinicalTrials.gov/show/NCT01623856 | Completed | Children’s Oncology Group | 2012-06-30 |
| NCT01584141 | Study of Lymphoma in Asia | https://ClinicalTrials.gov/show/NCT01584141 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT01565447 | Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters Study | https://ClinicalTrials.gov/show/NCT01565447 | Active, not recruiting | Oregon Health and Science University | 2020-12-31 |
| NCT01479387 | Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan | https://ClinicalTrials.gov/show/NCT01479387 | Completed | Bayer | NA |
| NCT04320992 | A Multicenter Prospective Study of “High Risk” Molecular Typing in Patients With Adult T Lymphoblastic Lymphoma | https://ClinicalTrials.gov/show/NCT04320992 | Recruiting | Sun Yat-sen University | 2023-03-31 |
| NCT04028804 | FLT PET: A Pilot Study in Lymphoma Patients | https://ClinicalTrials.gov/show/NCT04028804 | Completed | The Hospital for Sick Children | 2014-12-31 |
| NCT03930043 | A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin’s Lymphoma Patients | https://ClinicalTrials.gov/show/NCT03930043 | Recruiting | Ruijin Hospital | 2020-09-30 |
| NCT03706625 | Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment | https://ClinicalTrials.gov/show/NCT03706625 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2021-10-31 |
| NCT03571997 | Study of Prognostic Factors in Adult Lymphoblastic Lymphoma | https://ClinicalTrials.gov/show/NCT03571997 | Recruiting | PETHEMA Foundation | 2020-09-01 |
| NCT03480087 | Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma | https://ClinicalTrials.gov/show/NCT03480087 | Recruiting | Azienda Ospedaliera Città della Salute e della Scienza di Torino | 2020-07-31 |
| NCT03469921 | Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 | https://ClinicalTrials.gov/show/NCT03469921 | Completed | Institut Paoli-Calmettes | 2016-12-31 |
| NCT01264822 | Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori | https://ClinicalTrials.gov/show/NCT01264822 | Completed | Eisai Inc. | 2016-02-29 |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | https://ClinicalTrials.gov/show/NCT01199562 | Completed | City of Hope Medical Center | 2013-12-31 |
| NCT01196520 | Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM) | https://ClinicalTrials.gov/show/NCT01196520 | Completed | National Institutes of Health Clinical Center (CC) | 2015-12-31 |
| NCT01135849 | B-Receptor Signaling in Cardiomyopathy | https://ClinicalTrials.gov/show/NCT01135849 | Completed | Stanford University | 2010-10-31 |
| NCT01000753 | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | https://ClinicalTrials.gov/show/NCT01000753 | Active, not recruiting | Children’s Oncology Group | 2007-06-01 |
| NCT00949741 | Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin’s Lymphoma Patients | https://ClinicalTrials.gov/show/NCT00949741 | Completed | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | 2011-10-31 |
| NCT00902434 | Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era | https://ClinicalTrials.gov/show/NCT00902434 | Completed | Oncology Specialists, S.C. | 2011-02-28 |
| NCT00903890 | Cardiac Effects in Long-Term Survivors of Hodgkin’s and Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT00903890 | Active, not recruiting | University of Rochester | 2018-11-30 |
| NCT00903812 | IMPACT Non Hodgkins Lymphoma (NHL) Study | https://ClinicalTrials.gov/show/NCT00903812 | Completed | Amgen | 2008-12-31 |
| NCT00897325 | Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | https://ClinicalTrials.gov/show/NCT00897325 | Completed | Children’s Oncology Group | 2019-12-31 |
| NCT00898755 | Collecting and Storing Tissue From Young Patients With Cancer | https://ClinicalTrials.gov/show/NCT00898755 | Completed | Children’s Oncology Group | 2008-07-17 |
| NCT04283955 | A Retrospective Cohort Study: The Influence of MTHFR C677T and A1298C on the High-dose Methotrexate-Related Toxicities in Pediatric Patients With Non-Hodgkin Lymphoma | https://ClinicalTrials.gov/show/NCT04283955 | Completed | Sun Yat-sen University | 2019-03-01 |
| NCT01087333 | Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment | https://ClinicalTrials.gov/show/NCT01087333 | Recruiting | National Institutes of Health Clinical Center (CC) | NA |
| NCT00741325 | Long-Term Follow-up Study for Non-Hodgkin’s Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). | https://ClinicalTrials.gov/show/NCT00741325 | Completed | Sanofi | 2011-11-30 |
| NCT00713882 | Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors | https://ClinicalTrials.gov/show/NCT00713882 | Completed | Weill Medical College of Cornell University | 2008-11-30 |
| NCT00712556 | PET Study in Patients With Non-Hodgkin Lymphoma | https://ClinicalTrials.gov/show/NCT00712556 | Completed | Vanderbilt-Ingram Cancer Center | 2009-03-31 |
| NCT00685997 | Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas | https://ClinicalTrials.gov/show/NCT00685997 | Completed | UMC Utrecht | 2012-01-31 |
| NCT00626496 | Family Study of Lymphoproliferative Disorders | https://ClinicalTrials.gov/show/NCT00626496 | Recruiting | Mayo Clinic | 2025-12-31 |
| NCT00587912 | AIDS and Cancer Specimen Bank (ACSB) | https://ClinicalTrials.gov/show/NCT00587912 | Completed | Memorial Sloan Kettering Cancer Center | 2011-04-30 |
| NCT00579163 | Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | https://ClinicalTrials.gov/show/NCT00579163 | Active, not recruiting | Memorial Sloan Kettering Cancer Center | 2021-12-31 |
| NCT00510315 | Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant | https://ClinicalTrials.gov/show/NCT00510315 | Active, not recruiting | Memorial Sloan Kettering Cancer Center | 2021-01-31 |
| NCT00398177 | Clinical and Pathologic Studies in Non-Hodgkin’s Lymphoma and Hodgkin’s Disease | https://ClinicalTrials.gov/show/NCT00398177 | Recruiting | Stanford University | 2099-01-31 |
| NCT00341952 | Interdisciplinary Case-Control Study of Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT00341952 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT00301288 | A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL). | https://ClinicalTrials.gov/show/NCT00301288 | Completed | Royal Marsden NHS Foundation Trust | NA |
| NCT00240591 | Patients With Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab | https://ClinicalTrials.gov/show/NCT00240591 | Completed | GlaxoSmithKline | 2010-06-30 |
| NCT00240578 | Patients With Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With Iodine I 131 Tositumomab | https://ClinicalTrials.gov/show/NCT00240578 | Completed | GlaxoSmithKline | 2013-06-30 |
| NCT00098566 | Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT00098566 | Completed | Fred Hutchinson Cancer Research Center | 2011-06-30 |
| NCT00097565 | An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT00097565 | Completed | Genentech, Inc. | 2014-03-31 |
| NCT00003863 | Diagnostic Study of Patients With Aggressive Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT00003863 | Completed | Alliance for Clinical Trials in Oncology | 2005-05-31 |
| NCT00001301 | Chronic and Late Effects of Non-Hodgkin’s Lymphoma and Its Treatment in Long Term Survivors | https://ClinicalTrials.gov/show/NCT00001301 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT00001571 | A Pilot Study of Non-Hodgkin’s Lymphoma: Chemotherapy and Blood Levels of Organochlorines | https://ClinicalTrials.gov/show/NCT00001571 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT00026910 | Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin’s Lymphoma | https://ClinicalTrials.gov/show/NCT00026910 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT00001120 | A Study of Patients With AIDS Syndrome | https://ClinicalTrials.gov/show/NCT00001120 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | NA |
| NCT00339963 | Genome Expression in Lymphoma, Leukemia and Multiple Myeloma | https://ClinicalTrials.gov/show/NCT00339963 | Completed | National Institutes of Health Clinical Center (CC) | NA |
#If less then 500 registries
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | https://ClinicalTrials.gov/show/NCT04342117 | Recruiting | Verastem, Inc. | 2023-04-30 |
| NCT03199066 | Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL) | https://ClinicalTrials.gov/show/NCT03199066 | Recruiting | Czech Lymphoma Study Group | 2020-12-31 |
| NCT03117036 | Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III | https://ClinicalTrials.gov/show/NCT03117036 | Recruiting | Samsung Medical Center | 2022-02-28 |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry | https://ClinicalTrials.gov/show/NCT02298816 | Enrolling by invitation | Aurora Health Care | 2024-12-31 |
| NCT04220970 | Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | https://ClinicalTrials.gov/show/NCT04220970 | Recruiting | The Lymphoma Academic Research Organisation | 2032-06-07 |
| NCT03958916 | Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL | https://ClinicalTrials.gov/show/NCT03958916 | Recruiting | Sun Yat-sen University | 2022-05-05 |
| NCT03766516 | Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL | https://ClinicalTrials.gov/show/NCT03766516 | Recruiting | Samsung Medical Center | 2020-06-30 |
| NCT00889798 | Tumor Registry of Lymphatic Neoplasia | https://ClinicalTrials.gov/show/NCT00889798 | Completed | iOMEDICO AG | 2019-08-31 |
| NCT03971318 | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL | https://ClinicalTrials.gov/show/NCT03971318 | Recruiting | Sun Yat-sen University | 2022-05-05 |
| NCT03971305 | A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL | https://ClinicalTrials.gov/show/NCT03971305 | Recruiting | Sun Yat-sen University | 2022-05-05 |